A review of the advances in chronic obstructive pulmonary disease treatment

Journal of Pharmacy Practice

Volumn 25, Issue 6, 2012, Pages 576-582

  Metzger, Nicole L ^a   Lundquist, Lisa M ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

bronchodilators; chronic obstructive pulmonary disease; COPD; indacaterol; roflumilast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; INDACATEROL; IPRATROPIUM BROMIDE; LEVALBUTEROL; METHYLXANTHINE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ANTICHOLINERGIC EFFECT; BITTER TASTE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLAUCOMA; HEADACHE; HEART DISEASE; HEART RHYTHM; HUMAN; HYPOKALEMIA; LUNG FUNCTION; MORTALITY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHARMACIST; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINUS TACHYCARDIA; TASTE DISORDER; TREMOR; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84870951500     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012460828     Document Type: Review

References (19)

1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2011. http://www.goldcopd.org/. Accessed September 17, 2012.
2. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-the FDA's conclusions. N Engl J Med. 2010 ; 363 (12). 1097-1099
3. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011 ; 364 (12). 1093-1103
4. Stoloff SW. Chronic obstructive pulmonary disease megatrials; taking the results into office practice. Am J Med Sci. 2011 ; 342 (2). 160-167
5. Rabe KF. Treating COPD-the TORCH trial, p values, and the Dodo. N Engl J Med. 2007 ; 356 (8). 851-854 (Pubitemid 46294618)
6. Karner C, Cates CJ.. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination therapy alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011 ; 16 (3). CD008532
7. Calverly PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 ; 365 (8). 775-789 (Pubitemid 46294610)
8. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 ; 359 (15). 1543-1554
9. Van den Bruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pul Med. 2010 ; 10: 50
10. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 ; 300 (12). 1439-1450
11. Jenkins Cr, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009 ; 10: 59
12. East Hanover, NJ: Novartis Pharmaceuticals Corporation ; 2011:
13. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150mcg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pul Med. 2010 ; 10: 11
14. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C. Indacaterol once-daily provided superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011 ; 105 (5). 719-726
15. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010 ; 11: 135
16. Pulmonary-Allergy Drugs Advisory Committee. Addendum to FDA briefing package-clinical briefing document: NDA 22-383. March 2011. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Pulmonary-AllergyDrugsAdvisoryCommittee/UCM245638.pdf. Accessed September 9, 2011.
17. St. Louis, MO: Forest Pharmaceuticals, Inc ; 2011:
18. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005 ; 366 (9485). 563-571 (Pubitemid 41140331)
19. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised controlled trials. Lancet. 2009 ; 374 (9691). 685-694